AR063872A1 - Derivados de acetileno como inhibidores de estearoil coa desaturasa - Google Patents

Derivados de acetileno como inhibidores de estearoil coa desaturasa

Info

Publication number
AR063872A1
AR063872A1 ARP070105150A ARP070105150A AR063872A1 AR 063872 A1 AR063872 A1 AR 063872A1 AR P070105150 A ARP070105150 A AR P070105150A AR P070105150 A ARP070105150 A AR P070105150A AR 063872 A1 AR063872 A1 AR 063872A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
alkyl
case
cycloalkenyl
Prior art date
Application number
ARP070105150A
Other languages
English (en)
Inventor
Rakesh Datta
Neelima Khairatkar-Joshi
Shantaram Kashinath Phatangare
Dattaguru Anandrao More
Deepak Vitthal Ukride
Prasada Rao V S Lingam
Daisy Manis Shah
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of AR063872A1 publication Critical patent/AR063872A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente proporciona inhibidores de estearoil CoA desaturasa (SCD). En particular, los compuestos descriptos en la presente son útiles en el tratamiento o la prevención de enfermedades, condiciones y/o trastornos modulados por inhibidores de estearoil CoA desaturasa 1 (SCD1). También se proporcionan en la presente, procesos para preparar los compuestos descriptos en ella, los compuestos intermedios y su síntesis, composiciones farmacéuticas de éstas, y métodos para el tratamiento o prevención de enfermedades, condiciones y/o trastornos modulados por inhibidores de estearoil CoA desaturasa, como obesidad, trastorno del apetito, glucosa, insulina, lípidos, síndrome metabólico, enfermedad hígado adiposo. Reivindicación 1: Un compuesto de fórmula (1) A-U-B'-s-Q o una sal de ésta, un solvato de ésta, un profármaco de ésta, un estereoisómero de ésta o un N-óxido de ésta farmacéuticamente aceptables; donde: A es R'W-; R' se selecciona de alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquilalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, cicloalquenilalquilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, heteroarilalquilo sustituido o no sustituido, heterocíclico sustituido o no sustituido y heterociclilalquilo sustituido o no sustituido; W se selecciona de (CR1R2)p, C(=Y) , C(=Y)O, OC(=Y), O, CONR1, S(O)r, S(O)rNR1, NR1(CH2)nO, NR1 o NR1C(=Y)NR2; Q se selecciona de hidrógeno, hidroxilo, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquilalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, cicloalquenilalquilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, heteroarilalquilo sustituido o no sustituido, heterocíclico sustituido o no sustituido y heterociclilalquilo sustituido o no sustituido; (CR1R2)nOR5, COR1, COOR1, CONR1R2, S(O)rNR1R2, NR1R2, (CH2)nNR1R2, (CH2)nCHR1R2, (CR1R2)NR5R6, (CR1R2)NR5CONR6R7, (CH)nNHCOR1 y (CH2)nNHSO2R1; U se selecciona de un enlace y el grupo de fórmula (2), donde V es CR y N y B es CR o N, o B junto con un átomo de carbono con anillo adyacente y A forman un anillo seleccionado de fórmulas (3), B' se selecciona de fórmulas (4); U y V son independientemente CR o N; en cada caso, R se selecciona independientemente de hidrógeno, hidroxilo, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquilalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, cicloalquenilalquilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, heterociclilo sustituido o no sustituido, heterociclialquilo sustituido o no sustituido, heteroarilalquilo sustituido o no sustituido; en cada caso, m es independientemente un entero 0-4; en cada caso, n, n' y r son independientemente 0, 1 o 2; p es 0, 1, 2, 3, o 4; en cada caso, R1, R2, R5, R6 y R7 pueden ser idénticos o diferentes y se seleccionan independientemente de hidrógeno, halógeno, alquilo sustituido o no sustituido, alquenilo sustituido o no sustituido, alquinilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, cicloalquilalquilo sustituido o no sustituido, cicloalquenilo sustituido o no sustituido, cicloalquenilalquilo sustituido o no sustituido, arilo sustituido o no sustituido, arilalquilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, heterocíclico sustituido o no sustituido, heterociclialquilo sustituido o no sustituido, heteroarilalquilo sustituido o no sustituido; o, cuando R1 y R2 están unidos a un átomo común, forman con el átomo común un heterociclilo de 3-7 miembros; en cada caso X1 a X4 son independientemente N o CR; en cada caso, X y X5 a X7 son independientemente CHR4, CO, CS, O, S(O)r, N, o NR4; en cada caso, R4 se selecciona independientemente de hidrógeno, hidroxilo, alquilo sustituido o no sustituido, cicloalquilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, y heterociclilo sustituido o no sustituido; en cada caso, R3 se selecciona de hidrógeno, nitro, ciano, halógeno, COR1, alquilo sustituido o no sustituido, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, alcoxi sustituido o no sustituido, COOR1, CONR1R2, S(O)rR1, S(O)rNR1R2 y NR1R2, y en cada caso, Y es O o S.
ARP070105150A 2006-11-20 2007-11-20 Derivados de acetileno como inhibidores de estearoil coa desaturasa AR063872A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1917MU2006 2006-11-20
IN2175MU2006 2006-12-29
IN1375MU2007 2007-07-17
US95410807P 2007-08-06 2007-08-06

Publications (1)

Publication Number Publication Date
AR063872A1 true AR063872A1 (es) 2009-02-25

Family

ID=39322723

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105150A AR063872A1 (es) 2006-11-20 2007-11-20 Derivados de acetileno como inhibidores de estearoil coa desaturasa

Country Status (8)

Country Link
US (1) US20080182851A1 (es)
EP (1) EP2099755A2 (es)
JP (1) JP2010510201A (es)
KR (1) KR20090083477A (es)
AR (1) AR063872A1 (es)
AU (1) AU2007323193A1 (es)
TW (1) TW200831482A (es)
WO (1) WO2008062276A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2142529B1 (en) 2007-04-27 2013-12-25 Purdue Pharma LP Trpv1 antagonists and uses thereof
US7842696B2 (en) * 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
JP2011506348A (ja) * 2007-12-11 2011-03-03 メルク フロスト カナダ リミテツド ステアロイル−補酵素ａデルタ−９デサチュラーゼの阻害剤としての新規な複素環式芳香族化合物
CN102067099B (zh) * 2008-06-19 2013-03-27 惠普开发有限公司 多刀片互连器
US20110184027A1 (en) * 2008-09-25 2011-07-28 Glenmark Pharmaceuticals S.A. Tissue selective stearoyl-coa desaturase 1 inhibitors and cell based screening assay for their identification
US20100160323A1 (en) * 2008-12-23 2010-06-24 Alexander Bischoff NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
US9168248B2 (en) 2009-02-17 2015-10-27 Merck Canada Inc. Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
WO2011011872A1 (en) 2009-07-28 2011-02-03 Merck Frosst Canada Ltd. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US8962627B2 (en) 2009-10-30 2015-02-24 Prestwick Chemical, Inc. Oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
EP2423210A1 (de) 2010-08-25 2012-02-29 Bayer CropScience AG Heteroarylpiperidin- und -piperazinderivate als Fungizide
CA2815716C (en) 2010-10-27 2019-06-11 Bayer Intellectual Property Gmbh Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides
RU2621708C2 (ru) 2011-06-22 2017-06-07 ПУРДЬЮ ФАРМА Эл. Пи. Антагонисты trpv1, включающие дигидроксигруппу в качестве заместителя, и их применение
WO2013014039A1 (en) * 2011-07-28 2013-01-31 Nerviano Medical Sciences S.R.L. Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors
EP2766000A2 (en) 2011-10-15 2014-08-20 F.Hoffmann-La Roche Ag Scd1 antagonists for treating cancer
DK2921485T3 (en) 2011-12-27 2018-11-12 Bayer Cropscience Ag isoxazole
WO2013108026A1 (en) 2012-01-17 2013-07-25 Baltic Bio Ab Thiadiazolone derivatives useful in the treatment of diabetes
US9233102B2 (en) 2012-03-07 2016-01-12 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CA2873817A1 (en) 2012-05-22 2013-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Selective inhibitors of undifferentiated cells
EP3529245A4 (en) 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THE LATEST
EA201991650A1 (ru) 2017-01-06 2020-01-20 Юманити Терапьютикс, Инк. Способы лечения неврологических расстройств
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2024050408A1 (en) * 2022-08-30 2024-03-07 The Wistar Institute Of Anatomy And Biology Development of a novel ebna-1 degrader targeting through mdm2

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
US5274143A (en) * 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
AU2002230843B8 (en) * 2000-12-14 2007-05-17 Amylin Pharmaceuticals, Llc Peptide YY and peptide YY agonists for treatment of metabolic disorders
US6777432B1 (en) * 2001-09-04 2004-08-17 Darwin Molecular Corporation Pharmaceutical uses and synthesis of nicotinamides
PL220783B1 (pl) * 2002-03-13 2016-01-29 Janssen Pharmaceutica Nv Pochodna sulfonylowa, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
AU2003251933A1 (en) * 2002-07-25 2004-02-16 Wisconsin Alumni Research Foundation Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes
AU2004261250B2 (en) * 2003-07-29 2009-02-26 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
US7605161B2 (en) * 2003-07-30 2009-10-20 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
US7754711B2 (en) * 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
TWI345974B (en) * 2003-07-30 2011-08-01 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use in the inhibition of stearoyl-coa desaturase
AU2004261249B2 (en) * 2003-07-30 2008-09-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
PL1648880T3 (pl) * 2003-08-01 2010-06-30 Euro Celtique Sa Środki lecznicze użyteczne do leczenia bólu
JPWO2009048101A1 (ja) * 2007-10-10 2011-02-24 武田薬品工業株式会社 アミド化合物
US20100234383A1 (en) * 2009-03-13 2010-09-16 Gilles Klopman Treating, preventing or ameliorating a hyperproliferative disease/disorder

Also Published As

Publication number Publication date
JP2010510201A (ja) 2010-04-02
WO2008062276A8 (en) 2008-10-09
AU2007323193A1 (en) 2008-05-29
WO2008062276A2 (en) 2008-05-29
TW200831482A (en) 2008-08-01
KR20090083477A (ko) 2009-08-03
EP2099755A2 (en) 2009-09-16
WO2008062276A3 (en) 2009-03-05
US20080182851A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
AR063872A1 (es) Derivados de acetileno como inhibidores de estearoil coa desaturasa
RU2470011C2 (ru) Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов
AR074632A1 (es) Compuesto de amidofenoxiindazol, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util en el tratamiento de cancer
AR062886A1 (es) Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
RU2007106180A (ru) Производные индола, индазола или индолина
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
JP2011515483A5 (es)
AR035936A1 (es) Inhibidores de metaloproteinasas de matriz piridinica, derivados de piridina, composiciones farmaceuticas y usos de los mismos en la fabricacion de medicamentos
EP3800183A1 (en) Urea derivatives as trk-inhibiting compounds
UY31554A1 (es) Nuevos inhibidores de acetil coenzima a carboxilasa y usos en tratamientos de obesidad y diabetes mellitus
RU2015100901A (ru) Производные эфира гетероарилкарбоновой кислоты
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ECSP11011561A (es) Derivados aminobutíricos sustituidos como inhibidores de neprilisina
ECSP11011560A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
AR074876A1 (es) Derivados de indol-pirimidina para tratar cancer
ATE550337T1 (de) Modulatoren der glucocorticoidrezeptor-, ap-1- und/oder nf-kappa-b-aktivität und deren verwendung
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
RU2007125661A (ru) Арилоксиэтиламиновые и фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофимина-d2 и ингибирования повторного поглощения серотонина
RU2013136895A (ru) Новое бициклическое соединение или его соль
RU2014119711A (ru) Трициклические соединения, композиции, содержащие указанные соединения, и их применения
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
ECSP088257A (es) Derivados de amida
JP2015502371A5 (es)
RU2010107603A (ru) Производные n-(2-тиазолил)амида для лечения ожирения, диабетов и сердечно-сосудистых заболеваний
RU2017105262A (ru) Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств

Legal Events

Date Code Title Description
FB Suspension of granting procedure